Chatham Capital Group’s Labcorp LH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $347K | Sell |
1,240
-19
| -2% | -$5K | 0.04% | 181 |
|
|
2026
Q1 | $336K | Hold |
1,259
| – | – | 0.05% | 179 |
|
|
2025
Q4 | $316K | Hold |
1,259
| – | – | 0.04% | 180 |
|
|
2025
Q3 | $361K | Buy |
1,259
+1
| +0.1% | +$268 | 0.05% | 174 |
|
|
2025
Q2 | $330K | Hold |
1,258
| – | – | 0.05% | 179 |
|
|
2025
Q1 | $293K | Hold |
1,258
| – | – | 0.05% | 180 |
|
|
2024
Q4 | $288K | Buy |
1,258
+1
| +0.1% | +$229 | 0.05% | 177 |
|
|
2024
Q3 | $281K | Buy |
1,257
+19
| +2% | +$4.18K | 0.05% | 177 |
|
|
2024
Q2 | $252K | Hold |
1,238
| – | – | 0.04% | 177 |
|
|
2024
Q1 | $270K | Buy |
1,238
+1
| +0.1% | +$220 | 0.05% | 175 |
|
|
2023
Q4 | $281K | Buy |
1,237
+1
| +0.1% | +$210 | 0.06% | 171 |
|
|
2023
Q3 | $249K | Sell |
1,236
-203
| -14% | -$42.8K | 0.06% | 174 |
|
|
2023
Q2 | $298K | Hold |
1,439
| – | – | 0.06% | 166 |
|
|
2023
Q1 | $284K | Buy |
1,439
+1
| +0.1% | +$206 | 0.06% | 169 |
|
|
2022
Q4 | $291K | Hold |
1,438
| – | – | 0.07% | 165 |
|
|
2022
Q3 | $253K | Hold |
1,438
| – | – | 0.06% | 163 |
|
|
2022
Q2 | $290K | Hold |
1,438
| – | – | 0.07% | 162 |
|
|
2022
Q1 | $326K | Sell |
1,438
-232
| -14% | -$54.6K | 0.06% | 156 |
|
|
2021
Q4 | $451K | Hold |
1,670
| – | – | 0.08% | 149 |
|
|
2021
Q3 | $404K | Hold |
1,670
| – | – | 0.08% | 149 |
|
|
2021
Q2 | $396K | Hold |
1,670
| – | – | 0.08% | 150 |
|
|
2021
Q1 | $366K | Hold |
1,670
| – | – | 0.08% | 149 |
|
|
2020
Q4 | $292K | Hold |
1,670
| – | – | 0.07% | 147 |
|
|
2020
Q3 | $270K | Hold |
1,670
| – | – | 0.07% | 140 |
|
|
2020
Q2 | $238K | Buy |
+1,670
| New | +$231K | 0.06% | 146 |
|
|
2020
Q1 | – | Sell |
-1,670
| Closed | -$243K | – | 162 |
|
|
2019
Q4 | $243K | Hold |
1,670
| – | – | 0.06% | 150 |
|
|
2019
Q3 | $241K | Hold |
1,670
| – | – | 0.06% | 148 |
|
|
2019
Q2 | $248K | Hold |
1,670
| – | – | 0.06% | 152 |
|
|
2019
Q1 | $220K | Buy |
+1,670
| New | +$206K | 0.06% | 149 |
|
|
2018
Q4 | – | Sell |
-1,758
| Closed | -$262K | – | 158 |
|
|
2018
Q3 | $262K | Hold |
1,758
| – | – | 0.07% | 134 |
|
|
2018
Q2 | $271K | Hold |
1,758
| – | – | 0.07% | 132 |
|
|
2018
Q1 | $244K | Hold |
1,758
| – | – | 0.07% | 134 |
|
|
2017
Q4 | $241K | Hold |
1,758
| – | – | 0.07% | 135 |
|
|
2017
Q3 | $228K | Hold |
1,758
| – | – | 0.06% | 140 |
|
|
2017
Q2 | $233K | Sell |
1,758
-174
| -9% | -$21.3K | 0.06% | 143 |
|
|
2017
Q1 | $238K | Sell |
1,932
-29
| -1% | -$3.43K | 0.07% | 140 |
|
|
2016
Q4 | $216K | Sell |
1,961
-117
| -6% | -$13K | 0.06% | 135 |
|
|
2016
Q3 | $245K | Hold |
2,078
| – | – | 0.08% | 131 |
|
|
2016
Q2 | $233K | Hold |
2,078
| – | – | 0.07% | 135 |
|
|
2016
Q1 | $209K | Hold |
2,078
| – | – | 0.07% | 134 |
|
|
2015
Q4 | $221K | Sell |
2,078
-698
| -25% | -$72K | 0.07% | 133 |
|
|
2015
Q3 | $259K | Hold |
2,776
| – | – | 0.09% | 125 |
|
|
2015
Q2 | $289K | Hold |
2,776
| – | – | 0.08% | 133 |
|
|
2015
Q1 | $301K | Hold |
2,776
| – | – | 0.09% | 138 |
|
|
2014
Q4 | $257K | Hold |
2,776
| – | – | 0.08% | 144 |
|
|
2014
Q3 | $243K | Hold |
2,776
| – | – | 0.08% | 142 |
|
|
2014
Q2 | $244K | Hold |
2,776
| – | – | 0.1% | 100 |
|
|
2014
Q1 | $234K | Hold |
2,776
| – | – | 0.1% | 101 |
|
|
2013
Q4 | $218K | Hold |
2,776
| – | – | 0.09% | 109 |
|
|
2013
Q3 | $236K | Sell |
2,776
-669
| -19% | -$56.3K | 0.11% | 103 |
|
|
2013
Q2 | $296K | Buy |
+3,445
| New | +$286K | 0.14% | 97 |
|
Other funds holding LH
RRAM
JIC
BCWM
AAM
DIA
SFA
WCM
HPCM
MCM
ET
Chatham Capital Group's LH Position: Q2 2026 in Review
Chatham Capital Group reduced its Labcorp (LH) stake by 1.5% in Q2 2026, selling an estimated $5K and leaving 1,240 shares worth $347K. The position accounts for 0.04% of the portfolio, ranked #181.
Chatham Capital Group first reported a position in LH in Q2 2013 and has held it in 51 quarters since. The position peaked at $451K in Q4 2021. 265 funds tracked by Wall St. Rank hold LH as of Q2 2026.
- Chatham Capital Group held 1,240 shares of Labcorp worth $347K as of Q2 2026.
- Chatham Capital Group sold 19 Labcorp shares in Q2 2026, an estimated $5K.
- Labcorp made up 0.04% of Chatham Capital Group's portfolio in Q2 2026, its #181 holding.
- Chatham Capital Group first reported a position in Labcorp in Q2 2013 and has held it in 51 quarters since.
- Chatham Capital Group's Labcorp position peaked at $451K in Q4 2021.
- 265 funds tracked by Wall St. Rank held Labcorp as of Q2 2026.
Based on Chatham Capital Group's 13F filing for Q2 2026, filed 13 Jul 2026.